Organoids, which originate from stem cells, are a tool with great potential for modeling tissue and disease biology. The idea is to build miniature tissues and organs that accurately resemble and behave like their real counterparts. But there have been limitations to their development. A new study has taken organoids a step further by inducing intestinal stem cells to form tube-shaped epithelia with an accessible lumen and a similar spatial arrangement of crypt- and villus-like domains to that in vivo. These “mini-intestines” also retain key physiological hallmarks of the intestine and have a notable capacity to regenerate.
The work is published in Nature in the paper titled, “Homeostatic mini-intestines through scaffold-guided organoid morphogenesis.”
Organoids could complement animal testing by providing healthy or diseased human tissues, expediting the lengthy journey from lab to clinical trial. Beyond that, organoid technology may hold promise, in the long-term, to replace damaged tissues or even organs in the future. For example, by taking stem cells from a patient and growing them into a new liver, heart, kidney, or lung.
So far, established methods of making organoids come with considerable drawbacks: stem cells develop uncontrollably into circular and closed tissues that have a short lifespan, as well as non-physiological size and shape, all of which result in overall anatomical and/or physiological inconsistency with real-life organs.
Now, scientists from the group led by Matthias Lütolf, PhD, professor at EPFL’s Institute of Bioengineering, have found a way to “guide” stem cells to form an intestinal organoid that looks and functions just like real tissue. The method exploits the ability of stem cells to grow and organize themselves along a tube-shaped scaffold that mimics the surface of the native tissue, placed inside a microfluidic chip.
The researchers used a laser to sculpt the gut-shaped scaffold within a hydrogel, a soft mix of crosslinked proteins found in the gut’s extracellular matrix supporting the cells in the native tissue. Aside from being the substrate on which the stem cells could grow, the hydrogel thus also provides the form or “geometry” that would build the final intestinal tissue.
Once seeded in the gut-like scaffold, within hours, the stem cells spread across the scaffold, forming a continuous layer of cells with its characteristic crypt structures and villus-like domains. Then came a surprising result: the scientists found that the stem cells arranged themselves in order to form a functional tiny gut.
“It looks like the geometry of the hydrogel scaffold, with its crypt-shaped cavities, directly influences the behavior of the stem cells so that they are maintained in the cavities and differentiate in the areas outside, just like in the native tissue,” said Lütolf. The stem cells didn’t just adapt to the shape of the scaffold, they produced all the key differentiated cell types found in the real gut, with some rare and specialized cell types normally not found in organoids.
Intestinal tissues are known for the highest cell turnover rates in the body, resulting in a massive amount of shed dead cells accumulating in the lumen of the classical organoids that grow as closed spheres and require weekly breaking down into small fragments to maintain them in culture. “The introduction of a microfluidic system allowed us to efficiently perfuse these mini-guts and establish a long-lived homeostatic organoid system in which cell birth and death are balanced,” said Mike Nikolaev, a graduate student and the first author of the paper.
The researchers demonstrated that these miniature intestines share many functional features with their in vivo counterparts. For example, they can regenerate after massive tissue damage and they can be used to model inflammatory processes or host-microbe interactions in a way not previously possible with any other tissue model grown in the laboratory.
In addition, this approach is broadly applicable for the growth of miniature tissues from stem cells derived from other organs such as the lung, liver, or pancreas, and from biopsies of human patients. “Our work,” explained Lütolf, “shows that tissue engineering can be used to control organoid development and build next-gen organoids with high physiological relevance, opening up exciting perspectives for disease modeling, drug discovery, diagnostics, and regenerative medicine.”